Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 16, 2012

View Archived Issues

Chong Kun Dang Pharmaceutical divulges new CETP inhibitors

Researchers at Nutek Pharma prepare new anesthetic agents

Phase I trial of IMO-8400 begins, preclinical results presented

PTC-596 shows efficacy in a number of tumor models in vivo

Data presented on a novel EGFR inhibitor for patients with lung cancer

AstraZeneca will not exercise the option to acquire diabetes assets from Prosidion

Evotec and Haplogen partner to develop drugs for viral infectious diseases

Plasma ADMA as a biomarker to monitor PAH-targeted treatments

Tranzyme Pharma reports topline results from TZP-102 trial

TissueGene completes enrollment in phase II study of TG-C

Inovio Pharmaceuticals expands synthetic vaccine license with University of Pennsylvania

Bavarian Nordic's MVA-BN vaccine platform receives U.S. government contracts

Chinese researchers present new agents for HIV

Nanosphere receives FDA clearance to market test for CYP2C19 mutation

Merck & Co. prepares new NS5B inhibitors

RXi reports pharmacokinetic results from phase I study of candidate for dermal scarring

U.S. Department of Health & Human Services reports novel PLK1 inhibitor compounds

DNDi identifies chemical series targeting two neglected diseases

Epizyme and Eisai patent novel agents for cancer

Fujifilm provides update on development of micro-needle array delivery technology

Forest Laboratories and Adamas to develop fixed-dosed combination for Alzheimer's

Positive in vivo results support the advance of TVB-2640 into clinical studies

Immunovative Therapies expands collaboration with the University of Arizona

Investigators begin study of CNDO-201 in autism spectrum disorders

FDA approves Zilver PTX drug-eluting stent for peripheral arterial disease

New causative gene identified for primary torsion dystonia

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Aug. 3, 2026.
Tuojie Biotech (Shanghai) synthesizes new SARM1 inhibitors
BioWorld Science
Tuojie Biotech (Shanghai) Co. Ltd. has prepared and tested NAD(+) hydrolase SARM1 (SAMD2; MyD88-5) inhibitors found to be potentially useful for the treatment of...
Death in Chinese gene-editing trial exposes ethical fault lines
BioWorld
The death of a 6-year-old girl after receiving an experimental brain-directed gene-editing therapy at the Xinhua Hospital in Shanghai has reopened debate over how...
Seed funding at Adjuvia to treat mitochondrial dysfunction
BioWorld Science
Adjuvia Therapeutics Inc. has closed a $8 million series seed financing round to advance its work developing therapeutics to treat mitochondrial dysfunction and...
Replimune’s RP-1 for melanoma wins over FDA adcom
BioWorld
Following two complete response letters in the past year, Replimune Group Inc.’s RP-1 (suvolimogene oderparepvec) for unresectable metastatic cutaneous melanoma...